All eyes will be on ODYSSEY OUTCOMES, the first of the Late-Breaking Clinical Trials at the Annual Scientific Sessions of the American College of Cardiology this March.

This is the second completed cardiovascular outcomes study with a PCSK9 inhibitor. In contrast to FOURIER, ODYSSEY OUTCOMES has studied post-acute coronary syndrome patients rather than those with stable cardiovascular disease.